Senolytic drugs dasatinib, quercetin, and fisetin may influence longevity and age-related decline by affecting DNA methylation clocks.
February 2024 – Aging
Key takeaways
- Dasatinib, quercetin, and fisetin’s impact on ageing: These compounds may influence the ageing process by altering DNA methylation patterns, which are crucial for regulating gene expression and maintaining cellular function. By affecting these patterns, these drugs have the potential to slow down the biological mechanisms that lead to ageing
- Potential for lifespan and healthspan extension: By modulating biological markers of ageing, dasatinib, quercetin, and fisetin could contribute to extending not just the overall lifespan but also the period of life spent in good health. This suggests a significant potential for these compounds to enhance the quality of life as we age
- Modulation of biological age markers: The study indicates that these senolytic drugs can influence markers of biological age, such as DNA methylation clocks. These clocks are used to predict the biological age of tissues and cells, which can differ from chronological age, indicating the possibility of decelerating the ageing process at a molecular level
The findings open up new pathways for anti-ageing research, particularly in the development and use of senolytic therapy. The ability of dasatinib, quercetin, and fisetin to potentially reverse or slow ageing indicators at the DNA level underscores the importance of further studies to understand their mechanisms and optimise their use for anti-ageing interventions
Read the article at: Lee, Edwin, et al. Exploring the Effects of Dasatinib Quercetin and Fisetin on DNA Methylation Clocks: A Longitudinal Study on Senolytic Interventions. AGING, vol. 16, no. 4, 2024
